Background: Intestinal bacterial overgrowth as a consequence of postsurgical anatomical abnormalities as well as other small bowel diseases can lead to malabsorption. Case Report: A female patient had several abdominal operations due to recurrent intestinal obstructions. Initially, she presented with severe megaloblastic anaemia. Subsequently, she suffered from weight loss, diarrhoea, oedema, recurrent anaemia (despite vitamin B12 substitution), and severe malabsorption of proteins, lipids, iron, and vitamins. Vague information about the performed surgeries, an anatomy of the bowel that was difficult to interpret, and an unusual cholestasis made it difficult to reach the diagnosis of bacterial overgrowth due to a stagnant loop syndrome. Treatment with antibiotics only temporarily improved the condition of the patient. After restoring bowel continuity and after the resection of an enteroenteric fistula as well as of a bowel conglomerate, the patient did not show any further symptoms. Conclusion: The history of this patient indicates that the diagnosis of a stagnant loop syndrome may be difficult. The primary goal regarding surgically created small intestinal bacterial overgrowth should be the correction of the underlying small intestinal abnormality, whenever possible.

Keywords:
Stagnant loop syndrome, Small bowel overgrowth, Malnutrition, Anaemia
1.
King CE, Toskes PP: Bacterial overgrowth syndromes; in Berk JE (ed): Bockus Gastroenterology. Philadelphia, Saunders, 1985, pp 1781-1791.
2.
Husebye E: The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy 2005;51(suppl 1):1-22.
3.
Bures J, Cyrany J, Kohoutova D, et al: Small intestinal overgrowth syndrome. World J Gastroenterol 2010;16:2978-2990.
4.
Gregg CR, Toskes PP: Enteric bacterial flora and small bowel bacterial overgrowth syndrome; in Feldman M, Friedman LS, Sleisenger MH (eds): Gastrointestinal and Liver Disease. Philadelphia, Saunders, 2002, pp 1783-1793.
5.
Dibaise JK, Young RJ, Vanderhoof JA: Enteric microbial flora, bacterial overgrowth, and short-bowel syndrome. Clin Gastroenterol Hepatol 2006; 4:11-20.
6.
Buchman AL: Etiology and initial management of short bowel syndrome. Gastroenterology 2006;130: S5-15.
7.
Stein JM, Schneider AR: Bacterial overgrowth syndrome. Z Gastroenterol 2007;45:620-628.
8.
Quigley EMM, Quera R: Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 2006;130:S78-90.
9.
Corazza GR, Menozzi MG, Strocchi A, et al: The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology 1990;98:302-309.
10.
Saltzman JR, Kowdley KV, Pedrosa MC, et al: Bacterial overgrowth without malabsorption in elderly hypochloric subjects. Gastroenterology 1994;106:615-623.
11.
Weigand K, Weigand K: Percutaneous liver biopsy: retrospective study over 15 years comparing 287 inpatients with 428 outpatients. J Gastroenterol Hepatol 2009;24:792-799.
12.
Weigand K: Synthese, Verteilung und Bedeutung von Serumalbumin; in Ahnefeld FW (ed): Klinische Anästhesiologie und Intensivtherapie. Berlin, Springer, 1980, pp 52-64.
13.
Weigand K: Die Regulation des Serumalbuminspiegels unter physiologischen und pathologischen Bedingungen. Klin Wochenschr 1977;55:295-305.
14.
Weigand K: Gastrointestinaler Proteinverlust; in Aeberhard P, Koelz HR (eds): Gastroenterologische Pathologie. Berlin, Springer, 1987, pp 169-176.
© 2013 S. Karger GmbH, Freiburg
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.